<?xml version="1.0" encoding="UTF-8"?>
<p id="p0070">Among children with community-acquired RSV infections, palivizumab â€“based prophylaxis was given to 6/18 (33.3%), 6/6 (100%) and 4/4 (100%) of those for whom antiviral prophylaxis was recommended by the 1999 EMA, the 2007 French and the 2014 American guidelines, respectively.</p>
